Communiqués Hikma Pharmaceuticals PLC

Actions

HIK

GB00B0LCW083

Produits pharmaceutiques

Temps réel estimé Cboe Europe 12:36:31 14/09/2026			Varia. 5j.	Varia. 1 janv.
1 559,00 ^GBX	+1,83%		-2,62%	+0,52%

09/09	Hikma Pharmaceuticals soumet son spray nasal d'épinéphrine pour examen réglementaire aux États-Unis, en Europe, au Royaume-Uni et au Canada	CI
08/09	Hikma Pharmaceuticals PLC : Barclays révise sa recommandation à neutre	ZM

Communiqués

09/09	Hikma Pharmaceuticals : advances its epinephrine nasal spray with multi-market regulatory filings	PU
11/08	Hikma Pharmaceuticals : advances climate progress with first solar energy agreement	PU
22/07	Inspired at Hikma: Purpose-driven leadership, developing talent and building for growth. Meet Kristy Ronco	PU
23/06	Behind Better Health: Hikma's People	PU
22/06	Hikma Pharmaceuticals : welcomes FDA approval of Guardant360® Liquid CDx	PU
15/06	Supreme Court Addresses Induced Infringement Claims In Hikma v. Amarin	AQ
05/06	Hikma comments on Supreme Court of the United States unanimous decision in favour of Hikma	AQ
05/06	Hikma Pharmaceuticals puts access to medicines at the heart of its sustainability strategy, reaching 222 million patients worldwide	AQ
04/06	Hikma Pharmaceuticals : comments on Supreme Court of the United States’ unanimous decision in favour of	PU
04/06	Hikma Pharmaceuticals : puts access to medicines at the heart of its sustainability strategy, reaching 222 million patient...	PU
14/05	Inspired at Hikma: Career growth, leadership and social impact. Meet Zeena Murad	PU
08/05	Working at Hikma’s Zagreb R&D hub: meet Nera Marjanovic	PU
08/05	Hikma Pharmaceuticals : Why the world needs more companies like Hikma. By Said Darwazah, Chief Executive Officer	PU
05/05	Hikma Pharmaceuticals : and Marius Pharmaceuticals announce licensing agreement for KYZATREX® (testosterone undecanoate) C...	PU
28/04	Hikma Pharmaceuticals : announces settlement agreement for VYNDAMAX® (tafamidis)	PU
23/04	Hikma Pharmaceuticals : Results of our 2026 AGM	PU
23/04	Hikma Pharmaceuticals : Special Business passed at AGM	PU
23/04	Hikma Pharmaceuticals : Trading update April 2026	PU
23/04	Hikma Pharmaceuticals : reiterates full year 2026 guidance following encouraging start to the year	PU
16/04	Putting patients first through quality: a Q&A with Tyson Ardo, Associate Vice President, Quality	PU
18/03	Hikma Pharmaceuticals : Investing in R&D to drive high-value pipeline delivery	PU
18/03	Hikma Pharmaceuticals : Investing in manufacturing excellence at Hikma	PU
18/03	Hikma Pharmaceuticals : Investing in MENA to expand access and drive growth	PU
18/03	Hikma Pharmaceuticals : Investing in strategic partnerships driving growth in the US and MENA	PU
11/03	Hikma Pharmaceuticals : launches authorised generic of Nucynta® ER (tapentadol) extended-release in the US	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Hikma Pharmaceuticals : rentabilité supérieure aux attentes au S1 ; mais le titre nécessite des biosimilaires internes pour une revalorisation durable

Le 21 août 2026 à 17:06

Hikma poursuit sa baisse malgré Berenberg

Le 11 août 2026 à 11:38